Improvements in outcomes may be the result of better patient selection, researchers acknowledged however, they noted that the 2013-2017 cohort had several factors associated with increased risk for poor outcomes. These declines may be due in part to avoidance of the most toxic preparative regimens, according to the researchers. Jaundice, renal insufficiency, mechanical ventilation, high-level cytomegalovirus viremia, gram-negative bacteria, invasive mold infection, acute and chronic graft-versus-host disease and prednisone exposure all decreased in frequency between 20 compared with 20.įrequency of grade 3 or grade 4 acute GVHD declined from 14% in the earlier cohort to 12% in the later cohort (adjusted HR = 0.63 95% CI, 0.46-0.86), whereas frequency of chronic GVHD decreased by 60% (HR = 0.4 95% CI, 0.33-0.48). reduced-intensity conditioning, as well as among those whose allograft came from a matched sibling vs. Researchers observed similar reductions in overall mortality among patients who received myeloablative vs. Patients who received allogeneic HSCT between 20 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier.

They compared rates between the two cohorts of nonrelapse mortality before day 200 after transplant, cancer recurrence or progression, relapse-related mortality, and overall mortality adjusted for comorbidity scores, source of donor cells, donor type, patient age, disease severity, conditioning regimen, patient and donor sex, and cytomegalovirus serostatus. The researchers analyzed 1,148 patients (median age, 47.2 years range, 0.4-78.9) who underwent their first allogeneic HSCT between 20 at Fred Hutch’s clinical care partner, Seattle Care Alliance, and 1,131 patients (median age, 50 years range, 0.1-80.9) who received their first transplant between 20. McDonald and colleagues sought to determine whether improvement in survival continued during the past decade and to identify barriers to better outcomes.

The sum of these reductions was improved OS over the last decade, despite a patient population that was older and sicker in the most recent cohort.”Ĭlinical outcomes of allogeneic HSCT have improved during the past 50 years as a result of declines in transplant-related complications. “There were also reductions in the risk recurrence or progression of the cancers. McDonald, MD, member emeritus at Fred Hutchinson Cancer Research Center and professor of gastroenterology at University of Washington, told Healio.

“The most striking improvement was the continuing fall in the risk nonrelapse mortality - that is, deaths that occurred from complications of the transplant procedure, unrelated to the blood cancers for which the transplants were being carried out,” George B. Patients who received allogeneic hematopoietic stem cell transplants between 20 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier, according to results of a retrospective study published in Annals of Internal Medicine.

Allogeneic stem cell transplant